Loading company
$44.35+0.3%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 2, 2026
Past performance
- 1W
- +3.7%
- 1M
- +3.1%
- 3M
- -14.4%
- 6M
- -17.2%
- 1Y
- -56.8%
- 5Y
- +5.7%
$44.35+0.3%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 2, 2026
Just reported
From Boston Scientific Corporation's results release of October 28, 2026; its quarterly report has since been filed.
Actual
$5.14B
+1.4% y/y
-5.6% q/q
Guided
—
No guide given
Actual
$0.40
-22% y/y
-34% q/q
Guided
—
No guide given
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $5.1B | $5.1B | +1.44% |
| Profit | $580M | $755M | -23.18% |
| Profit per share | $0.40 | $0.51 | -21.57% |
| Free Cash Flow | $868M | $1.2B | -25.30% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
A short summary of each call — what the quarter showed, what management expects and whether they delivered on what they said last time — with the full transcript underneath.
“This has been a challenging year for Boston Scientific and I’m proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Boston Scientific Corporation’s Item 2.02 8-K filed October 28, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Actual
$828M
-21% y/y
-30% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Source: Yahoo Finance, transcribed by Quartr. Speaker names and roles are as transcribed; analysts are sometimes unnamed.
Call summaries are part of Pro
A two-minute read of every Boston Scientific Corporation earnings call: the numbers that mattered, what management expects, whether they delivered on last quarter’s outlook, and what analysts asked that went unanswered.
See one first on , , , or — open to everyone.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.